Clinico-pathologic factors associated with the occurrence of early and late metastatic spread in a cohort of breast cancer patients.

BACKGROUND AND OBJECTIVE Distant metastatic spread in breast cancer patients is a complex phenomenon involving several prognostic factors. We focused our analysis on early metastatic breast cancer (EMBC) (occurring during the first 36 months) versus late metastatic breast cancer (LMBC) (occurring beyond 3 years) in order to ascertain their possible differential predictive factors. METHODS diagnostic, surgical, and follow-up data were assessed for consecutive patients with breast cancer undergoing surgery between 1997 and 2019. We analysed the predictive factors for distant metastasis using both univariate and multivariate analysis. RESULTS The median follow-up for this cohort of 2708 patients was 89 months. The median metastasis-free interval (FMI) for metastasis patients was 38 months (17 months for EMBC group and 76 months for LMBC group). Distant metastases developed in 12.9% (350/2708); 48% (168/350) of them as EMBC and 52% (182/350) as LMBC. Loco-regional recurrence and nodal extracapsular extension were the only common predictors for both. CONCLUSIONS EMBC and LMBC appeared as two separate conditions, with a different outcome. In the EMBC group, tumour proliferation related factors were significant (histological grade, tumour size, body mass index), whereas for LMBC, other slow-acting factors seemed to be involved (screening program, tumour burden, bilateral tumour).

[1]  J. Sparano,et al.  The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes , 2021, Therapeutic advances in medical oncology.

[2]  S. González,et al.  Factors associated with the development of distant metastases in breast cancer patients—A regression model predicting organ relapse , 2020, The breast journal.

[3]  K. Friedrichs,et al.  Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study , 2019, Breast Cancer Research and Treatment.

[4]  S. Narod,et al.  The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer , 2018, Breast Cancer Research and Treatment.

[5]  S. Tyldesley,et al.  Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed , 2017, Breast Cancer Research and Treatment.

[6]  M. de Boer,et al.  Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? , 2015, British Journal of Cancer.

[7]  Keda Yu,et al.  Difference between observed and expected number of involved lymph nodes reflects the metastatic potential of breast cancer independent to intrinsic subtype , 2015, Oncotarget.

[8]  S. González,et al.  Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification , 2015, Clinical and Translational Oncology.

[9]  X. Pivot,et al.  A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. , 2014, Breast.

[10]  Mark J. Ratain,et al.  Tumour heterogeneity in the clinic , 2013, Nature.

[11]  Nuria Giménez,et al.  Differential survival and recurrence patterns of patients operated for breast cancer according to the new immunohistochemical classification: analytical survey from 1997 to 2012 , 2013, Tumor Biology.

[12]  L. Fallowfield,et al.  Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  L. Collins,et al.  Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer , 2012, Breast Cancer Research and Treatment.

[14]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Massagué,et al.  Molecular basis of metastasis. , 2008, The New England journal of medicine.

[16]  M. Namer,et al.  Prognostic factors in 1,038 women with metastatic breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Coebergh,et al.  An overview of prognostic factors for long-term survivors of breast cancer , 2007, Breast Cancer Research and Treatment.

[18]  J. Boyages,et al.  TUMOUR SIZE AS A PREDICTOR OF AXILLARY NODE METASTASES IN PATIENTS WITH BREAST CANCER , 2006, ANZ journal of surgery.

[19]  Wei Wei,et al.  Metastatic patterns in adenocarcinoma , 2006, Cancer.

[20]  Jenny C. Chang,et al.  Survival of patients with metastatic breast carcinoma , 2003, Cancer.

[21]  Kevin Hughes,et al.  Predicting the survival of patients with breast carcinoma using tumor size , 2002, Cancer.